Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.
Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.
In this video James discusses: